NCT04363684 ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
| NCT ID | NCT04363684 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Frontotemporal Lobar Degeneration (FTLD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,100 participants |
| Start Date | 2020-03-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,100 participants in total. It began in 2020-03-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Eligibility Criteria
Longitudinal Arm Inclusion Criteria Familial FTLD (f-FTLD) participants (either is acceptable): * members of families in whom at least one member has a known disease-associated mutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or other rare genes) * an autosomal dominant family history of a FTLD syndrome (without a known gene) verified by medical record review or well-documented family history including family members with a medical history consistent with FTLD or a related disorder. Sporadic FTLD (s-FTLD) participants: Sporadic participants should be symptomatic with no known family history nor a genetic mutation indicating f-FTLD. All sporadic participants must have an FTLD syndrome as a referring diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses will be excluded from longitudinal visits, but their baseline visit will be included in comparative datasets. For inclusion in the longitudinal follow-up, participants should meet research criteria for one of the following FTLD syndromes: * Progressive Supranuclear Palsy (PSP) * Semantic variant Primary Progressive Aphasia (svPPA) * Nonfluent variant Primary Progressive Aphasia (nfvPPA) * Corticobasal Degeneration (CBD)/Corticobasal Syndrome (CBS) * Behavioral variant Frontotemporal dementia (bvFTD) * Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD/ALS) Biofluid-Focused Arm Inclusion Criteria Participants enrolled in the biofluid arm may be either f-FTLD or s-FTLD. All general inclusion criteria apply. Participants should meet research criteria (as specified above) for any FTLD syndrome or meet familial FTLD inclusion criteria. Because the biofluid arm participants do not undergo the same detailed clinical and functional assessments required for the longitudinal arm, participants may be included regardless of primary language, as long as an appropriately translated consent is available. Exclusion Criteria: * Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic participant. * Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or biomarker evidence for Alzheimer's disease as a cause of the clinical syndrome. * A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5 years of onset of dementia), frequent alcohol or other substance intoxication, or other neurological disorder. * Evidence through history or laboratory testing of uncorrected B12 deficiency (B12 \< 95% of local laboratory's normal value), unregulated hypothyroidism (TSH \>150% of normal), HIV positive, renal failure (creatinine \> 2), liver failure (ALT or AST \> two times normal), respiratory failure that requires supplemental oxygen, large confluent white matter lesions, significant systemic medical illnesses such as deteriorating cardiovascular disease. * Current medication likely to affect CNS functions in the opinion of the site PI. * In the site investigator's opinion, the participant cannot complete sufficient key study procedures. The participant may be enrolled into the biofluid-focused arm if they can tolerate a blood draw and short clinical exam, but must be able to complete at least 75% of study procedures for enrollment into the longitudinal arm.
Contact & Investigator
Bradley Boeve, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT04363684 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Frontotemporal Lobar Degeneration (FTLD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04363684 currently recruiting?
Yes, NCT04363684 is actively recruiting participants. Contact the research team at forsberg.leah@mayo.edu for enrollment information.
Where is the NCT04363684 trial being conducted?
This trial is being conducted at Birmingham, United States, Los Angeles, United States, San Diego, United States, San Francisco, United States and 11 additional locations.
Who is sponsoring the NCT04363684 clinical trial?
NCT04363684 is sponsored by Mayo Clinic. The principal investigator is Bradley Boeve, MD at Mayo Clinic. The trial plans to enroll 2,100 participants.